Somatostatin
STS is a peptide produced by intestinal paracrine cells and plays a major role in inhibition of gastrointestinal (GI) endocrine secretion. Adverse events associated with SSAs are usually mild and include nausea, abdominal discomfort, bloating, fat malabsorption and gallstone formation.
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Although native STS binds all the five receptor subtypes, the synthetic analogues have different affinities for the STS receptors and exert their actions mainly interacting with subtypes 2 and 5 (see Table 2 ).
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More recently, pasireotide, a new SSA, has been developed and this molecule demonstrates higher affinity for subtypes 1, 2, 3 and 5.
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Somatostatin Receptors
The STS receptor is a G protein-coupled receptor present in the membranes of cells from various organs such as the endocrine and exocrine pancreas, GI tract, anterior pituitary and various regions of the brain. 18 There are five known STS receptor subtypes, and these subtypes may have different expression levels and functions depending on their location throughout the body (see Table 2 ).
Although these receptors are similar in their binding to S-14 and S-28, the binding affinity of each subtype is different for the SSAs. 19, 20 All STS receptor subtypes are coupled to adenylate cyclase through an inhibitory G protein, causing a reduction in intracellular cyclic adenosine monophosphate (cAMP) concentration when activated. 9 Furthermore, activation of the receptor may result in ion channel activation, decreasing the influx of calcium to the cell. 5 There is evidence that the STS receptors can change ligand-binding affinity and receptor internalisation through agonist-induced dimerisation. 21 Additionally, STS receptors can interact and form heterodimers with other families of receptors, and thus alter receptor signalling and provide novel molecular pathways for cell proliferation and survival.
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Antiproliferative Mechanisms
Based on many different in vitro and in vivo experimental models, the antitumour activity of SSAs has been demonstrated and is mediated through direct and indirect mechanisms. 22, [24] [25] [26] The activation of STS receptors can cause cytostatic and pro-apoptotic effects by direct activation of phosphotyrosine phosphatases (PTPs). 27, 28 PTPs control downstream signalling molecules such as the mitogen-activated proteins (MAPs) extracellular signal-regulated kinase (ERK)1 and ERK2, and ultimately induce antiproliferation by upregulation of cyclin-dependent kinase inhibitors. 22 The STS receptor subtypes 2 and 3 are involved with the pro-apoptotic mechanisms through the Antitumour Effects of Somatostatin Analogues in the Treatment of Neuroendocrine Tumours activation of pro-apoptotic genes such as p53 and bcl-2 (subtype 3), 29 the inhibition of the antiapoptotic effects of MAP kinase (subtype 2) 30 and the sensitisation of death receptors (subtypes 2 and 3). 31 In addition to direct effects, SST and SSAs exert a number of indirect antiproliferative, antiangiogenic and immunomodulatory effects. 13, 20, 32 These include: inhibition of the release of hormones and growth factors that aid tumour growth, such as insulin-like growth factor (IGF) and vascular endothelial growth factor (VEGF); reduction of tumour blood flow due to the suppression of endothelial cell proliferation; and arrest of monocyte migration (see Table 3 ).
Results from Previous Trials and Case Reports
More than 30 cases of partial tumour regression following octreotide administration, with or without other therapies, have been reported in the literature. 33, 34 Octreotide treatment of a patient with metastatic vasointestinal peptide (VIP)oma induced a reduction in the number and size of liver secondary tumours, as evidenced by computerised axial tomography, 35 and a similar finding has been reported in a patient with gastrinoma. 36 In addition, several case reports have documented complete histological regression of metastatic tumours after treatment with octreotide. 33, 37, 38 In addition to these case studies, several clinical studies have shown results suggesting that octreotide and lanreotide have antitumour activity in patients with progressive NETs. [39] [40] [41] [42] [43] [44] [45] [46] 
Results from the PROMID Study
PROMID was a randomised, double-blind, placebo-controlled trial conducted in 18 German academic centres. 47 The major criticism for this study was the lack of progression status prior to accrual. One of the great advantages of a prospective
Neuroendocrine Tumours Antiproliferative Activity randomised study is the understanding of tumour natural history in the placebo arm. In the placebo arm, 53 % of patients had progressed
by WHO criteria at six months; 79 % had progressed at 12 months;
and almost all had progressed at two years. for octreotide LAR and 6.0 months for placebo. The difference in tumour progression between the arms was 8.3 months. This is a robust and significant result, but is the benefit clinically meaningful?
The expected survival for a low-burden asymptomatic mid-gut NET is over seven years. Given this timeframe, the 8.3 month increase in TTP in the octreotide LAR arm does not initially seem a significant improvement; however, when studying the survival curve in the treatment arm closely, it becomes apparent that 16 patients had no progression and a long-lasting response for many years. Octreotide LAR appears to be a truly targeted agent, and a durable response in a third of the patient population is definitely clinically meaningful. A lowtoxicity intervention that induces a durable response and does not preclude future new interventions is the optimal treatment strategy for improving prognosis in NET patients. This is the main reason why patients with well-differentiated mid-gut NET should be offered SSAs independent of their tumour progression status or positivity on octreotide scan (Octreoscan™). SSAs are now accepted as the new standard treatment for patients with low-grade mid-gut NET.
In the PROMID study, median overall survival had not been reached in the treatment arm after 77.4 months of follow-up. In the placebo arm, the median overall survival was 73.7 months; however, this estimation was not robust due to the low number of deaths (p=0.77).
Since cross-over could occur after the trial had been unblinded, 77 % of the patients in the placebo arm received octreotide LAR, and additionally some patients in the placebo arm were treated with hepatic chemoembolisation, peptide receptor radionuclear therapy and chemotherapy. These therapeutic interventions may have had an undetermined effect, making the impact of octreotide LAR on patient survival difficult to assess.
Future Directions for Somatostatin Analogues
Results from the PROMID trial have proven the benefit of octreotide LAR treatment for patients with mid-gut NETs. The ongoing Controlled study of lanreotide antiproliferative response in NET (CLARINET) trial has been designed to examine the efficacy of lanreotide (autogel 120 mg) in the treatment of NETs. This trial is designed to assess whether lanreotide autogel prolongs the time to disease progression in patients with non-functioning NETs, including those of pancreatic origin. 48 Additionally, the activity of pasireotide as an antitumour agent is currently being investigated in a Phase II trial, whose goal is to determine whether pasireotide LAR can shrink or slow the growth of metastatic neuroendocrine carcinomas. 
Conclusion
The 
